BioWorld

Feb. 6, 2004

View Archived Issues

XenoPort's Prodrug Efforts Yield $37M Equity Round

Biogen Idec, Celltech Team Up On CD40 Ligand Drugs

Nuvelo Adds Dendreon's Heart Product To Thickening Pipeline

Correction

Anika Wins Orthovisc Approval After Long Development Road

Other News To Note

Renovis Prices $66M IPO; SGI, Exact Pull In Follow-On Funds

Renovis Inc. entered the public arena as the third biotech company to conduct an initial public offering this year, raising $66 million. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 14, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...